Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prospective Evaluation of Carvedilol in Prevention of Cardiac Toxicity in Patients with Metastatic HER2-positive Breast Cancer (S1501)
KCT0004843Phase 3Not yet recruiting
- Sponsor
- National Cancer Institute
- Start
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of carvedilol in HER2-enriched breast cancer (HER2+), Cardiotoxicity, sponsored by National Cancer Institute. Planned start Jan 2022; status: not yet recruiting.
02
Drugs
carvedilol
03
Conditions
HER2-enriched breast cancer (HER2+)Cardiotoxicity
Beyond the preview
Go deeper on KCT0004843.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0004843.